Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Abivax SA Sponsored ADR ( (ABVX) ) has shared an update.
On May 4, 2026, Abivax SA agreed to repurchase all outstanding royalty certificates issued in 2022 from existing holders for a total of $90 million, paying $45 million in cash and $45 million via an interest-free vendor’s loan that will be converted into 403,347 American Depositary Shares. The royalty certificates will be cancelled, simplifying Abivax’s capital structure and materially reducing a royalty overhang that had weighed on future commercialization economics.
The equity component is structured as a $45 million capital increase through an offering of new ADSs to the royalty holders at $111.57 per ADS, based on a five-day volume-weighted average price, resulting in about 0.5% dilution for existing shareholders. Abivax reported that its cash, cash equivalents and short-term investments totaled €530.4 million as of December 31, 2025, and that its projected cash runway remains into the fourth quarter of 2027, indicating that the transaction is aimed more at balance sheet optimization and financial flexibility than near-term liquidity needs.
The new ordinary shares underlying the ADSs are expected to be admitted to trading on Euronext Paris and the ADSs on Nasdaq around May 7, 2026, following the filing of a prospectus supplement to register potential resales of the 403,347 ADSs by the holders. By eliminating the royalty liability and keeping its cash runway unchanged, Abivax strengthens its financial profile ahead of potential commercialization of obefazimod and signals a more shareholder-friendly capital structure to investors in both Europe and the United States.
The most recent analyst rating on (ABVX) stock is a Buy with a $175.00 price target. To see the full list of analyst forecasts on Abivax SA Sponsored ADR stock, see the ABVX Stock Forecast page.
Spark’s Take on ABVX Stock
According to Spark, TipRanks’ AI Analyst, ABVX is a Neutral.
The score is held down primarily by weak operating fundamentals (zero revenue in 2025, widening losses, and heavy cash burn). Technicals also lean bearish with the price below key moving averages and negative MACD. The main stabilizer is the improved balance sheet with low leverage and a larger equity base.
To see Spark’s full report on ABVX stock, click here.
More about Abivax SA Sponsored ADR
Abivax SA is a clinical-stage biotechnology company based in France and the United States, focused on developing therapeutics that harness natural regulatory mechanisms to stabilize the immune response in chronic inflammatory diseases. Its lead drug candidate, obefazimod (ABX464), is in Phase 3 trials for treating moderately to severely active ulcerative colitis, positioning the firm in the advanced inflammatory bowel disease segment.
Abivax’s shares trade on Euronext Paris and its American Depositary Shares are listed on the Nasdaq Global Market under the ticker “ABVX,” giving the company dual-market access to European and U.S. investors and broadening its financing options for late-stage clinical and pre-commercial activities.
Average Trading Volume: 942,903
Technical Sentiment Signal: Buy
Current Market Cap: $10.28B
See more data about ABVX stock on TipRanks’ Stock Analysis page.